Previous 10 | Next 10 |
Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today reported encouraging findings from the outpatient stage of a Phase 2 proof-...
Rebound hypoglycemia observed in the placebo arm with oral glucose tablet use; No rebound hypoglycemia observed in the RTU glucagon treatment arm Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and com...
Xeris Pharmaceuticals ( XERS -6.4% ) enters into a non-exclusive agreement with unlicensed medicine distributor Clinigen Group plc for the supply and distribution of Gvoke (glucagon injection) outside of the U.S. on a "named patient" basis while its marketing application in Europe is und...
Xeris Pharmaceuticals (NASDAQ: XERS ) announces an exclusive agreement with Clinigen Group to manage the supply and distribution of Gvoke outside of U.S. where Gvoke is not currently licensed. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced an exclusive agreement with Clinigen Group plc (AIM: CLIN,...
SIFCO (NYSEMKT: SIF ) +61% on Q2 results . More news on: SIFCO Industries, Inc., United Natural Foods, Inc., Cyclacel Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Image source: The Motley Fool. Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading
Xeris Pharmaceuticals, Inc. (XERS) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Allison Wey – Senior Vice President-Investor Relations and Corporate Communication Paul Edick – Chairman and Chief Executive Officer Barry Deutsch –...
Xeris Pharmaceuticals (NASDAQ: XERS ): Q1 GAAP EPS of -$0.89 misses by $0.05 . More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Gvoke™ Pre-Filled Syringe (PFS) net sales of $1.7 million in Q1 2020 Gvoke HypoPen™ on track for planned launch in July 2020 Initiated programs to ensure easier patient access to GVOKE in the midst of the COVID-19 pandemic Corporate actions taken to conserve ca...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Xeris Pharmaceuticals Inc. Website:
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...
Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achievin...